VaxGen gains $877.5M US contract for anthrax vaccine
California, USA-based VaxGen says that the US government has awarded the company an $877.5 million contract to supply 75 million doses of anthrax vaccine for civilian defense.
The contract, the first of its kind under the Project BioShield Act of 2004, is intended to provide enough product to vaccinate 25 million Americans in a multiple-dose regimen against inhalation anthrax, the most-deadly form of the disease and the one most likely to be used as a bioterrorist weapon.
The contract calls on VaxGen to provide 25 million doses of its recombinant Protective Antigen anthrax vaccine to the Strategic National Stockpile within two years of the award and a total of 75 million doses within three years. For the remainder of the five-year contract, VaxGen will maintain active manufacturing operations and providing stockpile-related services.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze